A screening on the NCI-60 tumor cell panel revealed that about 75% of tumor cell lines were found to have defective IFN responses.13,41 However, the same does not necessarily apply to primary tumor cells13 and in-patient situations, in which primary resistance phenomena toward oncolytic virotherapy have been observed in various clinical trials. The gene discussed is IFNA1; the disease is neoplasm.